Tumor Biology

, Volume 36, Issue 5, pp 3345–3354 | Cite as

Decorin is responsible for progression of non-small-cell lung cancer by promoting cell proliferation and metastasis

  • Xuefei Shi
  • Wenjun Liang
  • Wen Yang
  • Rui Xia
  • Yong Song
Research Article


Decorin, a member of the small leucine-rich proteoglycans family, exists and plays multifunctional roles in stromal and epithelial cells. Emerging evidences showed that decorin is dysregulated expression in a wide variety of human tumors and affects a broad biology process of cancer cells, including growth, metastasis, and angiogenesis. Recent studies demonstrated that decorin could affect A549 proliferation though decreasing TGF-β1, cycling D1 expression and increasing P53 and P21 expression. However, limited data are available on the effect of decorin on metastasis of non-small-cell lung cancer (NSCLC) cell lines and how decorin impacts metastasis is still unknown. In this study, we identified decorin mRNA expression through Oncomine database and verified the expression of decorin mRNA and protein in 50 patients who underwent primary surgical resection of a NSCLC in the Department of Thoracic Surgery, Jinling Hospital, Nanjing University School of Medicine, China, between September 2013 and March 2014 by quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR) and Western blot. Also, the correlationship between decorin and the NSCLC patients’ clinical characteristics or survival ( was analyzed. Via ectopic expression analyses and Western blot, the roles of decorin in proliferation, metastasis, and the underline mechanism for decorin expression were further explored. We found that decorin was downregulated in NSCLC tissues compared with the adjacent normal lung tissues or normal tissues. Additionally, the expression of decorin was correlated with tumor size, lymph node metastasis, tumor stage, and prognosis. We also showed that overexpression of decorin could inhibit NSCLC cell lines proliferation and metastasis. Through Western blot analysis, we identified that E-cadherin and vascular endothelial growth factor (VEGF) are two key factors responsible for the growth arrest and metastasis inhibition induced by decorin in NSCLC. Our results indicated that decorin plays crucial roles in NSCLC against carcinogenesis and progression. Decorin might be a predictive factor and an attractive therapeutic target for NSCLC patients.


Decorin NSCLC Proliferation Metastasis 



Non-small-cell lung cancer


American Cancer Society


Extracellular matrix


Small leucine-rich repeat proteoglycans


Fetal bovine serum


Phenylmethanesulfonyl fluoride


Overall survival


Epithelial-mesenchymal transition


Vascular endothelial growth factor



This work was supported by grants from the National Natural Science Foundation of China (No. 81170064) and the Natural Science Foundation of China (No. 81302032). We apologize to all researchers whose relevant contributions were not cited due to space limitations.

Conflict of interest



  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer J clinicians. 2014;64(1):9–29. doi: 10.3322/caac.21208.Google Scholar
  2. 2.
    Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, et al. Non-small cell lung cancer. J Natl Compr Cancer Netw. 2010;8(7):740–801.Google Scholar
  3. 3.
    Wu YL, Zhou Q. Clinical trials and biomarker research on lung cancer in China. Expert Opin Ther Targets. 2012;16 Suppl 1:S45–50. doi: 10.1517/14728222.2011.630663.CrossRefPubMedGoogle Scholar
  4. 4.
    Lazar V, Suo C, Orear C, van den Oord J, Balogh Z, Guegan J, et al. Integrated molecular portrait of non-small cell lung cancers. BMC Med Genet. 2013;6:53. doi: 10.1186/1755-8794-6-53.Google Scholar
  5. 5.
    Zochbauer-Muller S, Gazdar AF, Minna JD. Molecular pathogenesis of lung cancer. Annu Rev Physiol. 2002;64:681–708. doi: 10.1146/annurev.physiol.64.081501.155828.CrossRefPubMedGoogle Scholar
  6. 6.
    Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80. doi: 10.1056/NEJMra0802714.CrossRefPubMedGoogle Scholar
  7. 7.
    Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29(24):3316–21. doi: 10.1200/jco.2010.33.3757.CrossRefGoogle Scholar
  8. 8.
    Baghy K, Horvath Z, Regos E, Kiss K, Schaff Z, Iozzo RV, et al. Decorin interferes with platelet-derived growth factor receptor signaling in experimental hepatocarcinogenesis. The FEBS J. 2013;280(10):2150–64. doi: 10.1111/febs.12215.CrossRefPubMedGoogle Scholar
  9. 9.
    Horvath Z, Kovalszky I, Fullar A, Kiss K, Schaff Z, Iozzo RV, et al. Decorin deficiency promotes hepatic carcinogenesis matrix biology. J Int Society Matrix Biology. 2014;35:194–205. doi: 10.1016/j.matbio.2013.11.004.CrossRefGoogle Scholar
  10. 10.
    Ferdous Z, Wei VM, Iozzo R, Hook M, Grande-Allen KJ. Decorin-transforming growth factor-interaction regulates matrix organization and mechanical characteristics of three-dimensional collagen matrices. Int J Biol Chem. 2007;282(49):35887–98. doi: 10.1074/jbc.M705180200.CrossRefGoogle Scholar
  11. 11.
    Hocking AM, Shinomura T, McQuillan DJ. Leucine-rich repeat glycoproteins of the extracellular matrix biology. J Int Society for Matrix Biology. 1998;17(1):1–19.CrossRefGoogle Scholar
  12. 12.
    Bi X, Pohl NM, Qian Z, Yang GR, Gou Y, Guzman G, et al. Decorin-mediated inhibition of colorectal cancer growth and migration is associated with E-cadherin in vitro and in mice. Carcinogenesis. 2012;33(2):326–30. doi: 10.1093/carcin/bgr293.CrossRefPubMedGoogle Scholar
  13. 13.
    Iozzo RV, Schaefer L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. The FEBS J. 2010;277(19):3864–75. doi: 10.1111/j.1742-4658.2010.07797.x.CrossRefPubMedGoogle Scholar
  14. 14.
    Dil N, Banerjee AG. A role for aberrantly expressed nuclear localized decorin in migration and invasion of dysplastic and malignant oral epithelial cells. Head & neck oncology. 2011;3:44. doi: 10.1186/1758-3284-3-44.CrossRefGoogle Scholar
  15. 15.
    Buraschi S, Neill T, Owens RT, Iniguez LA, Purkins G, Vadigepalli R, et al. Decorin protein core affects the global gene expression profile of the tumor microenvironment in a triple-negative orthotopic breast carcinoma xenograft model. PLoS One. 2012;7(9):e45559. doi: 10.1371/journal.pone.0045559.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Gu Y, Zhang S, Wu Q, Xu S, Cui Y, Yang Z, et al. Differential expression of decorin, EGFR and cyclin D1 during mammary gland carcinogenesis in TA2 mice with spontaneous breast cancer. J experimental & clinical cancer res CR. 2010;29:6. doi: 10.1186/1756-9966-29-6.CrossRefGoogle Scholar
  17. 17.
    Hu Y, Sun H, Owens RT, Wu J, Chen YQ, Berquin IM et al. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia (New York, NY). 2009;11(10):1042–53.Google Scholar
  18. 18.
    Yu X, Zou Y, Li Q, Mao Y, Zhu H, Huang G, et al. Decorin-mediated inhibition of cholangiocarcinoma cell growth and migration and promotion of apoptosis are associated with E-cadherin in vitro tumour biology. J Int Society Oncodevelopmental Biology and Medicine. 2014;35(4):3103–12. doi: 10.1007/s13277-013-1402-y.CrossRefGoogle Scholar
  19. 19.
    Campioni M, Ambrogi V, Pompeo E, Citro G, Castelli M, Spugnini EP, et al. Identification of genes down-regulated during lung cancer progression: a cDNA array study. J experimental & clinical cancer research : CR. 2008;27:38. doi: 10.1186/1756-9966-27-38.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Liang S, Xu JF, Cao WJ, Li HP, Hu CP. Human decorin regulates proliferation and migration of human lung cancer A549 cells. Chin Med J. 2013;126(24):4736–41.PubMedGoogle Scholar
  21. 21.
    Gyorffy B, Surowiak P, Budczies J, Lanczky A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013;8(12):e82241. doi: 10.1371/journal.pone.0082241.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Wei C, Wang X, Chen M, Ouyang K, Song LS, Cheng H. Calcium flickers steer cell migration. Nature. 2009;457(7231):901–5. doi: 10.1038/nature07577.CrossRefPubMedGoogle Scholar
  23. 23.
    Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (New York, NY). 2007;9(2):166–80.Google Scholar
  24. 24.
    Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A. 2001;98(24):13784–9. doi: 10.1073/pnas.241500798.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Bi XL, Yang W. Biological functions of decorin in cancer. Chinese journal of cancer. 2013;32(5):266–9. doi: 10.5732/cjc.012.10301.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi: 10.1016/j.cell.2011.02.013.CrossRefPubMedGoogle Scholar
  27. 27.
    Nash MA, Deavers MT, Freedman RS. The expression of decorin in human ovarian tumors clinical cancer research. J Am Association for Cancer Res. 2002;8(6):1754–60.Google Scholar
  28. 28.
    Smid-Koopman E, Blok LJ, Chadha-Ajwani S, Helmerhorst TJ, Brinkmann AO, Huikeshoven FJ. Gene expression profiles of human endometrial cancer samples using a cDNA-expression array technique: assessment of an analysis method. Br J Cancer. 2000;83(2):246–51. doi: 10.1054/bjoc.2000.1238.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Leygue E, Snell L, Dotzlaw H, Troup S, Hiller-Hitchcock T, Murphy LC et al. Lumican and decorin are differentially expressed in human breast carcinoma. The Journal of pathology. 2000;192(3):313–20. doi: 10.1002/1096-9896(200011)192:3 < 313::aid-path694 >;2-b.
  30. 30.
    Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, et al. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer clinical cancer research. J Am Association for Cancer Research. 2003;9(1):207–14.Google Scholar
  31. 31.
    Sofeu Feugaing DD, Gotte M, Viola M. More than matrix: the multifaceted role of decorin in cancer. Eur J Cell Biol. 2013;92(1):1–11. doi: 10.1016/j.ejcb.2012.08.004.CrossRefPubMedGoogle Scholar
  32. 32.
    Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol. 2003;19:207–35. doi: 10.1146/annurev.cellbio.19.011102.111135.CrossRefPubMedGoogle Scholar
  33. 33.
    Jawhari A, Farthing M, Pignatelli M. The importance of the E-cadherin-catenin complex in the maintenance of intestinal epithelial homoeostasis: more than intercellular glue? Gut. 1997;41(5):581–4.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol. 1993;5(5):806–11.CrossRefPubMedGoogle Scholar
  35. 35.
    Wijnhoven BP, Dinjens WN, Pignatelli M. E-cadherin-catenin cell-cell adhesion complex and human cancer. The British J surg. 2000;87(8):992–1005. doi: 10.1046/j.1365-2168.2000.01513.x.CrossRefGoogle Scholar
  36. 36.
    Doki Y, Shiozaki H, Tahara H, Inoue M, Oka H, Iihara K, et al. Correlation between E-cadherin expression and invasiveness in vitro in a human esophageal cancer cell line. Cancer Res. 1993;53(14):3421–6.PubMedGoogle Scholar
  37. 37.
    Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 1994;54(14):3929–33.PubMedGoogle Scholar
  38. 38.
    Frixen UH, Behrens J, Sachs M, Eberle G, Voss B, Warda A, et al. E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol. 1991;113(1):173–85.CrossRefPubMedGoogle Scholar
  39. 39.
    Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993;53(7):1696–701.PubMedGoogle Scholar
  40. 40.
    Bi X, Tong C, Dockendorff A, Bancroft L, Gallagher L, Guzman G, et al. Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis. 2008;29(7):1435–40. doi: 10.1093/carcin/bgn141.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Neill T, Painter H, Buraschi S, Owens RT, Lisanti MP, Schaefer L, et al. Decorin antagonizes the angiogenic network: concurrent inhibition of Met, hypoxia inducible factor 1alpha, vascular endothelial growth factor A, and induction of thrombospondin-1 and TIMP3. J biological chem. 2012;287(8):5492–506. doi: 10.1074/jbc.M111.283499.CrossRefGoogle Scholar
  42. 42.
    Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, Iozzo RV. Decorin suppresses tumor cell-mediated angiogenesis. Oncogene. 2002;21(31):4765–77. doi: 10.1038/sj.onc.1205595.CrossRefPubMedGoogle Scholar
  43. 43.
    D’Amico TA. Angiogenesis in non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2004;16(1):13–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Qi L, Zhu F, Li SH, Si LB, Hu LK, Tian H. Retinoblastoma binding protein 2 (RBP2) promotes HIF-1alpha-VEGF-induced angiogenesis of non-small cell lung cancer via the Akt pathway. PLoS One. 2014;9(8):e106032. doi: 10.1371/journal.pone.0106032.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Shijubo N, Kojima H, Nagata M, Ohchi T, Suzuki A, Abe S, et al. Tumor angiogenesis of non-small cell lung cancer. Microsc Res Tech. 2003;60(2):186–98. doi: 10.1002/jemt.10257.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Xuefei Shi
    • 1
  • Wenjun Liang
    • 1
  • Wen Yang
    • 1
  • Rui Xia
    • 2
  • Yong Song
    • 1
    • 3
  1. 1.Department of Respiratory Medicine, Jinling HospitalNanjing University School of MedicineNanjingChina
  2. 2.Department of Biochemistry and Molecular BiologyNanjing Medical UniversityNanjingChina
  3. 3.Department of Respiratory Medicine, Jinling HospitalMedical School of Nanjing UniversityNanjingChina

Personalised recommendations